2005
DOI: 10.1007/s11904-005-0013-7
|View full text |Cite
|
Sign up to set email alerts
|

The population effectiveness of highly active antiretroviral therapy: Are good drugs good enough?

Abstract: Despite the success of highly active antiretroviral therapy (HAART) at reducing mortality from HIV infection, there is evidence that it is not reaching the all of the population that needs it, even in the developed world. To be maximally effective at the population level, all persons with HIV infection must be diagnosed; those persons with an indication for HAART must enter care, must receive HAART, and then must adhere to appointments and, finally, HAART itself. There is considerable evidence that significant… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
32
0

Year Published

2010
2010
2018
2018

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 35 publications
(32 citation statements)
references
References 53 publications
0
32
0
Order By: Relevance
“…23 Retention in care was defined as having completed at least one visit for HIV primary care in each of 3 or 4 quarter years in the year after diagnosis. 24 Based on treatment recommendations at the time, 25 ART initiation within 1 year of diagnosis was assessed for patients with a baseline CD4+ T cell count less than 350 cells/mm 3 and was dichotomized. Adherence to ART was assessed by average responses on a visual analogue scale of adherence, using all available follow up reports for the participant.…”
Section: Trust Variables and Outcomesmentioning
confidence: 99%
See 1 more Smart Citation
“…23 Retention in care was defined as having completed at least one visit for HIV primary care in each of 3 or 4 quarter years in the year after diagnosis. 24 Based on treatment recommendations at the time, 25 ART initiation within 1 year of diagnosis was assessed for patients with a baseline CD4+ T cell count less than 350 cells/mm 3 and was dichotomized. Adherence to ART was assessed by average responses on a visual analogue scale of adherence, using all available follow up reports for the participant.…”
Section: Trust Variables and Outcomesmentioning
confidence: 99%
“…1,2 To maximally benefit from ART, patients with HIV must be diagnosed as early as possible, linked to HIV care, retained in care, prescribed ART, and adhere to ART and have an undetectable HIV load. [3][4][5] Unfortunately, among the patients aware of their HIV status, fewer than three-quarters are linked to care in a timely manner and further less than two-thirds are retained in HIV care. 6 As a result, the U.S. Centers for Disease Control and Prevention estimates that of the 1.2 million people in the United States live with human immunodeficiency virus (HIV) infection, only 30% currently have viral suppression.…”
Section: Introductionmentioning
confidence: 99%
“…35,36,38 Adherence to HIV care is a more comprehensive concept than adherence to HAART, and encompasses medication adherence as one of its elements. 4,5 The validation analyses conducted in this study suggest that within the context of adherence to HIV care, intention is a clinically important variable. Furthermore, the factor analysis found that intention was a single factor rather than a three or four component construct.…”
Section: Discussionmentioning
confidence: 82%
“…2,3 Adherence to HIV care is a concept that includes attendance at appointments and adherence to HAART regimens. 4,5 These two components have been shown to have independent associations with long-term healthcare outcomes. More than 10% of patients taking HAART report missing one or more doses of medications per day, and > 33% report missing doses over a 2-to 4-week period.…”
Section: Introductionmentioning
confidence: 99%
“…Blood collected at interview was tested for CD4 for 69 respondents and for VL for 61 respondents; first CD4 and/ or VL was available from subsequent monitoring of reports to surveillance for an additional 27 respondents (CD4) and an additional 16 respondents (VL). Of 96 respondents for whom CD4 count was available either through the Never in Care Pilot or a later report to surveillance, 47% had counts of 350 cells/cubic millimeter (mm 3 ) and 20% had counts of 200 cells/ mm 3 ; 44% of the 77 people with VL results had a VL of .100,000 copies/milliliter (mL). Table 3 describes respondents' health and relationship with the health-care system.…”
Section: Resultsmentioning
confidence: 99%